tozadenant Articles
ANN meeting highlights: Novartis' Gilenya, Lundbeck's Azilect, Orion's ODM-101, Biotie's tozadenant
21 March 2013
Biotie's Parkinson's drug tozadenant clears Phase IIb study
11 December 2012
Showing 1-4 of 4 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
